News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Vivek Subbiah: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies
Vivek Subbiah/LinkedIn
Apr 19, 2025, 08:05

Vivek Subbiah: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn about recent paper he and his colleagues co-authored:

“Delighted to share our latest publication in American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology – courtesy of our brilliant colleagues from London led by Dr. Elisa Fontana.

FGFR is clearly a tissue-agnostic target but we need to find the right dose for the right patient with right alteration.

Thrilled to collaborate with amazing colleagues Tobias Arkenau, Charles Swanton.”

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials

Authors: Rafael Grochot, Tobias Arkenau, Charles Swanton, Vivek Subbiah, Elisa Fontana, et al.

Vivek Subbiah: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies

More posts featuring Vivek Subbiah.

cancer Cancer research Charles Swanton Elisa Fontana OncoDaily Oncology Tobias Arkenau Vivek Subbiah
Special Coverage
Blog
May 9, 2025, 10:04
Aakash Desai: AI in Predicting EGFR Mutations from Whole Slide Images in Lung Cancer
Blog
May 9, 2025, 09:39
Yakup Ergün: One of the Key Upcoming Presentations at ESMO Breast 2025
Blog
May 9, 2025, 09:37
Erika Hamilton: PROTAC Data at ASCO25 in the MBC Oral Session
Blog
May 9, 2025, 09:29
ESO - M2ICOS Project Launches Fellowship Program to Support Oncology Training and Mobility in the EU
Science
May 9, 2025, 09:22
Myeloma Paper of the Day, May 9th, suggested by Robert Orlowski
Drugs
May 9, 2025, 09:15
Penpulimab: Uses in Cancer, Side Effects, Dosage, Expectations, and More
Drugs
May 9, 2025, 08:47
Jonathan Pachter: FDA Grants Accelerated Approval for 1st Targeted Therapy in KRAS-Mutant LGSOC
Blog
May 9, 2025, 08:15
Parminder Singh: Grand Rounds at Mayo Clinic
Science
May 9, 2025, 08:02
Ashish Kamat: Predictive Value of AI Histologic Biomarker CHAI in NMIBC Treatment
Drugs
May 9, 2025, 07:54
Rahul Banerjee: Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma
Blog
May 9, 2025, 07:41
Eric Singhi: First-Year Fellow’s Graduation from the Singhi Clinic
Science
May 9, 2025, 07:24
Elizabeth McKenna: Study on Early- and Older-Onset Cancer Trends in the U.S. by Meredith Shiels and colleagues